Additionally, exploring the combination of ARPC1B‐targeted therapies with other treatment modalities, such as immunotherapy or targeted therapy, may offer synergistic benefits in treating pancreatic cancer. The gene discussed is ARPC1B; the disease is familial pancreatic carcinoma.